External Quality Controls

SARS Complete Panel

Respiratory Viral Panel

STI Panel

HPV Panel

Gastrointestinal Panel

ONBOARDx Kits

Proficiency Testing

Genital Ulcer Panel

Proudly Supporting Over 100+ Customers with Leading Diagnostic Solutions

“Microbix approached us before the pandemic started, and the relationship developed so easily and quickly that we formalized our collaboration in 2020. Along with their excellent technical capabilities, they have successfully developed relationships with many diagnostics manufacturers around the world. We are pleased that our FLOQSwabs® are their exclusive choice for their growing line of swab formatted QAPs™”

Gaetano Natale, Chief Commercial Officer.

The Microbix Difference

Our Quality Commitment

By choosing Microbix Biosystems Inc., you are aligning with a partner certified to the latest ISO standards and dedicated to delivering products that truly set the benchmark for quality in the industry.

Decades of Expertise

With over three decades of experience in the global diagnostics industry, Microbix has established a reputation as a leading infectious disease diagnostic manufacturer.

Widespread Customer Acceptance

Microbix’s products have consistently earned widespread recognition and trust from customers due to their superior reliability.

Download Our Full Product Catalogue

DOWNLOAD PRODUCT CATALOGUE

News & Insights from Our Diagnostics Experts

Microbix Presenting at Muskoka Capital Event

Microbix announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 26 to 28, 2025.

September 25, 2025
Microbix’s Corporate Presentation

Profitable growth from supporting next generation Diagnostics. Click below to download..

September 23, 2025
Microbix Assisting EMQN with Second Genetic-Test EQA Program

and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with faster and slower than normal metabolism of the widely-prescribed antiplatelet (anti-clotting) drug Clopidogrel (brand named Plavix®).

September 23, 2025